{"transactions":[{"id":2106372,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2022-11-22T21:07:30.000Z","date":"2022-11-20","kind":"tax_withholding","acquired":false,"shares":25057,"price":10.85,"value":271868.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":384714,"source":{"system":"sec-edgar","filing":"0001415889-22-011671","document":"form4-11222022_091120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922011671/form4-11222022_091120.xml","form_type":"4"}},{"id":2106371,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2022-11-22T21:07:30.000Z","date":"2022-11-18","kind":"sale","acquired":false,"shares":65000,"price":11.0191,"value":716241.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022."}],"balance_after":409771,"source":{"system":"sec-edgar","filing":"0001415889-22-011671","document":"form4-11222022_091120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922011671/form4-11222022_091120.xml","form_type":"4"}},{"id":2175799,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2022-08-23T23:00:28.000Z","date":"2022-08-19","kind":"tax_withholding","acquired":false,"shares":25676,"price":9.34,"value":239813.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":473507,"source":{"system":"sec-edgar","filing":"0001415889-22-008983","document":"form4-08232022_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922008983/form4-08232022_040813.xml","form_type":"4"}},{"id":2201254,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2022-07-27T22:56:09.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 1, 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On June 30 2022, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2023, subject to the reporting person's continued service."}],"balance_after":499183,"source":{"system":"sec-edgar","filing":"0001415889-22-008006","document":"form4-07272022_030759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922008006/form4-07272022_030759.xml","form_type":"4"}},{"id":2257769,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2022-05-24T23:17:27.000Z","date":"2022-05-20","kind":"tax_withholding","acquired":false,"shares":3365,"price":8.74,"value":29410.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,263 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022."}],"balance_after":479183,"source":{"system":"sec-edgar","filing":"0001415889-22-005631","document":"form4-05242022_040517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922005631/form4-05242022_040517.xml","form_type":"4"}},{"id":2377315,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2022-02-23T23:29:44.000Z","date":"2022-02-18","kind":"tax_withholding","acquired":false,"shares":25973,"price":9.61,"value":249600.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":481285,"source":{"system":"sec-edgar","filing":"0001415889-22-001699","document":"form4-02232022_030232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922001699/form4-02232022_030232.xml","form_type":"4"}},{"id":2483429,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-12-07T00:53:00.000Z","date":"2021-12-02","kind":"grant","acquired":true,"shares":340000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 2, 2021, the reporting person was granted 340,000 RSUs. 240,000 RSUs are subject to service-based vesting conditions and the remaining 100,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment."}],"balance_after":507258,"source":{"system":"sec-edgar","filing":"0001179110-21-010638","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021010638/edgar.xml","form_type":"4"}},{"id":2497113,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2021-11-24T01:22:36.000Z","date":"2021-11-19","kind":"tax_withholding","acquired":false,"shares":1350,"price":8.36,"value":11286.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1228 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2021."}],"balance_after":167258,"source":{"system":"sec-edgar","filing":"0001415889-21-005466","document":"form4-11232021_051122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588921005466/form4-11232021_051122.xml","form_type":"4"}},{"id":2591891,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-08-24T22:55:27.000Z","date":"2021-08-20","kind":"tax_withholding","acquired":false,"shares":17464,"price":14.05,"value":245369.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":167380,"source":{"system":"sec-edgar","filing":"0001179110-21-008394","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021008394/edgar.xml","form_type":"4"}},{"id":2698229,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-05-24T22:10:57.000Z","date":"2021-05-20","kind":"tax_withholding","acquired":false,"shares":942,"price":17.8,"value":16767.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,082 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 14, 2021."}],"balance_after":184844,"source":{"system":"sec-edgar","filing":"0001179110-21-005842","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021005842/edgar.xml","form_type":"4"}},{"id":2838138,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-02-23T23:07:16.000Z","date":"2021-02-20","kind":"tax_withholding","acquired":false,"shares":3984,"price":18.79,"value":74859.36,"ownership":{"direct":true},"balance_after":184704,"source":{"system":"sec-edgar","filing":"0001179110-21-002160","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021002160/edgar.xml","form_type":"4"}},{"id":2868534,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-02-10T22:43:55.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 553 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 13, 2020."}],"balance_after":188688,"source":{"system":"sec-edgar","filing":"0001179110-21-001536","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021001536/edgar.xml","form_type":"4"}},{"id":3048391,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-24T22:24:36.000Z","date":"2020-08-20","kind":"tax_withholding","acquired":false,"shares":4323,"price":18.22,"value":78765.06,"ownership":{"direct":true},"balance_after":123135,"source":{"system":"sec-edgar","filing":"0001179110-20-009265","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020009265/edgar.xml","form_type":"4"}},{"id":3073847,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-29T21:05:33.000Z","date":"2020-07-27","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 1 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On July 27, 2020, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2021, subject to the reporting person's continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 968 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020."}],"balance_after":127458,"source":{"system":"sec-edgar","filing":"0001179110-20-008540","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020008540/edgar.xml","form_type":"4"}},{"id":3252010,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-25T00:08:49.000Z","date":"2020-02-20","kind":"tax_withholding","acquired":false,"shares":7060,"price":25.9,"value":182854.0,"ownership":{"direct":true},"balance_after":106490,"source":{"system":"sec-edgar","filing":"0001179110-20-002146","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020002146/edgar.xml","form_type":"4"}},{"id":3288145,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-05T23:58:54.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 1 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On February 3, 2020, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service."}],"balance_after":113550,"source":{"system":"sec-edgar","filing":"0001179110-20-001200","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020001200/edgar.xml","form_type":"4"}},{"id":3288144,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-05T23:58:54.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":43550,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":93550,"source":{"system":"sec-edgar","filing":"0001179110-20-001200","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020001200/edgar.xml","form_type":"4"}},{"id":3467319,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2019-07-03T22:05:11.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised with respect to the first 25% of the shares subject to this option when optionee completes 12 months of continuous service after the Grant Date. This option may be exercised with respect to an additional 1/48th of the shares subject to this option when optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on the 4-year anniversary of the Grant Date provided optionee has remained in continuous service through such date."}],"balance_after":260000,"derivative":{"exercise_price":16.94,"expiration_date":"2029-06-30","underlying":"Ordinary Shares","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001179110-19-008497","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019008497/edgar.xml","form_type":"4"}},{"id":3467318,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-07-03T22:05:11.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001179110-19-008497","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019008497/edgar.xml","form_type":"4"}},{"id":3600147,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-12T16:15:35.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":15075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019."}],"balance_after":15075,"derivative":{"exercise_price":13.51,"expiration_date":"2029-03-08","underlying":"Common Stock","underlying_shares":15075},"source":{"system":"sec-edgar","filing":"0001209191-19-018791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119018791/doc4.xml","form_type":"4"}},{"id":3600146,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-12T16:15:35.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":9045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022."}],"balance_after":15639,"source":{"system":"sec-edgar","filing":"0001209191-19-018791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119018791/doc4.xml","form_type":"4"}},{"id":3636715,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-02-25T16:15:47.000Z","date":"2019-02-21","kind":"tax_withholding","acquired":false,"shares":877,"price":13.38,"value":11734.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":6594,"source":{"system":"sec-edgar","filing":"0001209191-19-012966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119012966/doc4.xml","form_type":"4"}},{"id":3718332,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-27T08:11:29.000Z","date":"2018-12-22","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":7471,"source":{"system":"sec-edgar","filing":"0001209191-18-064141","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118064141/doc4.xml","form_type":"4"}},{"id":3742187,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-06T08:05:23.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":753,"price":20.5556,"value":15478.3668,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."}],"balance_after":5171,"source":{"system":"sec-edgar","filing":"0001209191-18-061104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118061104/doc4.xml","form_type":"4"}},{"id":3771807,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-07T16:05:12.000Z","date":"2018-11-05","kind":"tax_withholding","acquired":false,"shares":879,"price":20.28,"value":17826.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":5924,"source":{"system":"sec-edgar","filing":"0001209191-18-057552","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118057552/doc4.xml","form_type":"4"}},{"id":3818771,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-12T16:11:48.000Z","date":"2018-09-10","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":6803,"source":{"system":"sec-edgar","filing":"0001209191-18-050629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118050629/doc4.xml","form_type":"4"}},{"id":3914512,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-05-30T07:51:39.000Z","date":"2018-05-25","kind":"sale","acquired":false,"shares":42615,"price":24.2639,"value":1034006.0985,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $24.25 to $24.35 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":4503,"source":{"system":"sec-edgar","filing":"0001209191-18-034062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118034062/doc4.xml","form_type":"4"}},{"id":3933530,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-05-15T07:57:38.000Z","date":"2018-05-13","kind":"tax_withholding","acquired":false,"shares":3930,"price":24.35,"value":95695.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were delivered to the issuer by the reporting person from vested restricted stock awards to cover tax liability in connection with vesting of those awards."}],"balance_after":47118,"source":{"system":"sec-edgar","filing":"0001209191-18-030094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118030094/doc4.xml","form_type":"4"}},{"id":4034876,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Common Stock","published_at":"2018-02-26T08:29:21.000Z","date":"2018-02-22","kind":"grant","acquired":true,"shares":5742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":51048,"source":{"system":"sec-edgar","filing":"0001209191-18-013209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118013209/doc4.xml","form_type":"4"}},{"id":4143000,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Common Stock","published_at":"2017-12-05T07:40:14.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":817,"price":20.5436,"value":16784.1212,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.20 to $20.85 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":45306,"source":{"system":"sec-edgar","filing":"0001209191-17-063696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117063696/doc4.xml","form_type":"4"}},{"id":4316452,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Common Stock","published_at":"2017-05-17T15:57:26.000Z","date":"2017-05-15","kind":"sale","acquired":false,"shares":7704,"price":15.7475,"value":121318.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $15.60 to $15.90 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":46123,"source":{"system":"sec-edgar","filing":"0001209191-17-033030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117033030/doc4.xml","form_type":"4"}},{"id":4335914,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-05-03T16:18:24.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% to vest at the end of six months after the grant date and the remaining 75% to vest in equal quarterly installments over the remainder of such two year period."}],"balance_after":65000,"derivative":{"exercise_price":16.5,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-17-029654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117029654/doc4.xml","form_type":"4"}},{"id":4405877,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-03T16:34:31.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017."}],"balance_after":11500,"derivative":{"exercise_price":27.475,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001209191-17-017596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117017596/doc4.xml","form_type":"4"}},{"id":4405876,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Common Stock","published_at":"2017-03-03T16:34:31.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020."}],"balance_after":53827,"source":{"system":"sec-edgar","filing":"0001209191-17-017596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117017596/doc4.xml","form_type":"4"}},{"id":4533945,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":122121,"kind":"person","name":"Hindman Andrew A.","position":1,"cik":"0001607965","reported_name":"Hindman Andrew A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Dev. Officer"}}],"security":"Common Stock","published_at":"2016-12-05T17:09:27.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":443,"price":20.7225,"value":9180.0675,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.35 to $21.15 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":49227,"source":{"system":"sec-edgar","filing":"0001209191-16-153403","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116153403/doc4.xml","form_type":"4"}}]}